Fermer le menu

 

 

 

  • The Independent Data Safety and Monitoring Board (DSMB) confirmed the remarkable efficacy results and a positive benefit/risk profile of MaaT013 in this patient population
  • The Company plans for submission with the European Medicines Agency in June 2025, targeting a potential approval in mid-2026

 

 

Read the press release

Plus d'infos